Premium
Immunotherapy: MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression (Adv. Funct. Mater. 12/2019)
Author(s) -
Liu Xiaowei,
Feng Yanlin,
Xu Guangchao,
Chen Yang,
Luo Ya,
Song Jinen,
Bao Yu,
Yang Jiqiao,
Yu Chune,
Li Yanna,
Ye Haoyu,
Ke Bowen,
Chen Bo,
Hu Jianping,
Xu Jie,
Meng Huan,
Zhang Haiyuan,
Shi Hubing
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201970079
Subject(s) - blockade , nanocarriers , cancer research , materials science , mesoporous silica , melanoma , immunotherapy , drug delivery , immune checkpoint , tumor microenvironment , t cell , immune system , nanotechnology , medicine , biology , immunology , tumor cells , receptor , mesoporous material , biochemistry , catalysis
In article number 1806916 , Haiyuan Zhang, Hubing Shi, and co‐workers provide a novel framework for combining targeted therapy and immune checkpoint blockade by using a mesoporous silica nanoparticle (MSNP) system. The MSNP‐carried MEK inhibitor is specifically enriched in the tumor microenvironment, and selectively internalized by tumor cells rather than T‐cells. The cellular‐specific delivery avoids T‐cell toxicity and synergizes oncogene‐targeted therapy and PD‐1 blockade.